0001415889-24-010604.txt : 20240409 0001415889-24-010604.hdr.sgml : 20240409 20240409180018 ACCESSION NUMBER: 0001415889-24-010604 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240405 FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS STEPHEN CENTRAL INDEX KEY: 0001131146 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 24833738 MAIL ADDRESS: STREET 1: ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-04092024_060410.xml X0508 4 2024-04-05 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001131146 DAVIS STEPHEN C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 true true false false CEO 0 Common Stock 2024-04-05 4 M 0 17333 A 136175 D Common Stock 2024-04-05 4 M 0 34666 A 170841 D Common Stock 2024-04-08 4 S 0 8858 17.87 D 161983 D Common Stock 2024-04-08 4 S 0 17716 17.87 D 144267 D Restricted Stock Units 2024-04-05 4 M 0 17333 0 D Common Stock 17333 34667 D Restricted Stock Units 2024-04-05 4 M 0 34666 0 D Common Stock 34666 138666 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The restricted stock units vest in four equal annual installments beginning April 5, 2023. Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. /s/ Jennifer J. Rhodes, Attorney-in-Fact 2024-04-09